摘要
背景:前列腺癌是一种在男性生殖系统中的腺体前列腺中的异常细胞生长的疾病。虽然老年人和家族病史被认为是前列腺癌的危险因素,但这种癌症的病因仍不清楚。目前,前列腺癌是所有人种男性癌症死亡的主要原因之一。 方法:在这篇综述中,我们首先探讨病毒感染对前列腺癌的影响,随后总结在过去的几年里溶瘤病毒治疗前列腺癌的发展。 结果:越来越多的证据表明,各种病毒感染是可能导致前列腺癌的发病机制。现有的研究提供了强有力的证据,至少有两个病毒(RXMV,HPV)将可以导致前列腺变为肿瘤,而且会影响恶性前列腺癌患者生活质量。传统的治疗方法包括化疗和放疗不能区分癌细胞和正常细胞,这是一个严重的缺点,将会增加前列腺癌患者在治疗过程中的毒性反应。到目前为止,很少有其他方法可用于治疗晚期前列腺癌患者。溶瘤病毒可以通过病毒复制和细胞毒性蛋白的表达对基因改造诱导癌细胞裂解。 结论:病毒治疗正在发展成为癌症的新疗法,它采用亲瘤的和溶瘤的病毒通过自己的能力找到并破坏体内肿瘤细胞。溶瘤病毒是一种相对较新的抗肿瘤免疫治疗药物,对溶瘤病毒使用治疗前列腺癌的道路仍然有一些障碍。
关键词: 前列腺癌,病毒,基因突变,病毒治疗,溶瘤病毒,亲瘤病毒。
Current Cancer Drug Targets
Title:Virus, Oncolytic Virus and Human Prostate Cancer
Volume: 17 Issue: 6
关键词: 前列腺癌,病毒,基因突变,病毒治疗,溶瘤病毒,亲瘤病毒。
摘要: Background: Prostate cancer (PCa), a disease, is characterized by abnormal cell growth in the prostate - a gland in the male reproductive system. Although older age and a family history of the disease have been recognized as the risk factors of PCa, the cause of this cancer remains unclear. Currently, PCa is one of the leading causes of cancer death among men of all races.
Method: In this review study, we first discuss the controversy of the contribution of virus infection to PCa, and subsequently summarize the development of oncolytic virotherapy for PCa in the past several years. Results: Mounting evidence suggests that infections with various viruses are causally linked to PCa pathogenesis. Published studies have provided strong evidence that at least two viruses (RXMV and HPV) contribute to prostate tumourigenicity and impact on the survival of patients with malignant PCa. Traditional therapies including chemotherapy and radiotherapy are unable to distinguish cancer cells from normal cells, which are a significant drawback and leads to toxicities for PCa patients undergoing treatment. So far, few other options are available for treating patients with advanced PCa. For PCa treatment, oncolytic virotherapy appears to be much more attractive, which uses live viruses to selectively kill cancer cells. Oncolytic viruses can be genetically engineered to induce cancer cell lysis through virus replication and expression of cytotoxic proteins. Conclusion: Virotherapy is being developed to be a novel therapy for cancers, which uses oncotropic and oncolytic viruses with their abilities to find and destroy malignant cells in the body. As oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents, several important barriers still exist on the road to the use of oncolytic viruses for PCa therapy.Export Options
About this article
Cite this article as:
Virus, Oncolytic Virus and Human Prostate Cancer, Current Cancer Drug Targets 2017; 17 (6) . https://dx.doi.org/10.2174/1568009616666161216095308
DOI https://dx.doi.org/10.2174/1568009616666161216095308 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Of Humans and Hamsters: The Hamster Buccal Pouch Carcinogenesis Model as a Paradigm for Oral Oncogenesis and Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Heterocyclization of Thiophenes Derived from Estrone Followed by Cytotoxic, HTRF Kinase and Pim-1 Kinase Evaluations
Anti-Cancer Agents in Medicinal Chemistry Electrochemically Driven Supramolecular Interaction of Quinones and Ferrocifens: An Example of Redox Activation of Bioactive Compounds
Current Topics in Medicinal Chemistry Effect of Some Triterpene Glycosides Applied in vitro on Chromatin State in Human Cells
Current Bioactive Compounds AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer
Current Cancer Drug Targets Curcumin Combats against Gastrointestinal Cancer: A Review of Current Knowledge Regarding Epigenetics Mechanisms with a Focus on DNA Methylation
Current Medicinal Chemistry Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology The Effect of A Hexanoic Acid Linker Insertion on the Pharmacokinetics and Tumor Targeting Properties of the Melanoma Imaging Agent 99mTc-HYNIC-cycMSH
Anti-Cancer Agents in Medicinal Chemistry STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Combination of Anti-EGFR Drugs with Anti-Angiogenic or Other Signal Transduction Inhibitors as a Rational Approach to Cancer Therapy
Current Cancer Therapy Reviews New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Machine Learning and Perturbation Theory Machine Learning (PTML) in Medicinal Chemistry, Biotechnology, and Nanotechnology
Current Topics in Medicinal Chemistry Gene Selection for the Discrimination of Colorectal Cancer
Current Molecular Medicine Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Organic Synthesis Preparation of Multifunctional Nanoprobes for Tumor-Targeted Fluorescent Imaging and Therapy
Current Drug Targets Relationship between Gut Microbiota, Gut Hyperpermeability and Obesity
Current Medicinal Chemistry